Montie J E, Stewart B H, Straffon R A, Banowsky L H, Hewitt C B, Montague D K
J Urol. 1977 Mar;117(3):272-5. doi: 10.1016/s0022-5347(17)58429-3.
The results of therapy for 78 patients with disseminated renal cell carcinoma are evaluated. Symptoms related to the primary tumor were noted in only 28 per cent of the patients and were not difficult to manage in those patients not undergoing nephrectomy. Adjuctive nephrectomy, therefore, is a more appropriate term than palliative nephrectomy when referring to removal of the primary tumor as part of an aggresive combined therapeutic approach. Of patients receiving an adjunctive nephrectomy those with osseous metastases only had a better 1-year survival rate (36 per cent) than those with metastases to other sites (18 per cent). Complete regression of metastases was noted in 12 per cent of patients treated with medroxyprogesterone acetate and adjunctive nephrectomy. The role of adjunctive nephrectomy combined with embolic infarction, hormonal therapy, chemotherapy and/or immunotherapy is discussed.
对78例弥漫性肾细胞癌患者的治疗结果进行了评估。仅28%的患者出现与原发肿瘤相关的症状，对于未接受肾切除术的患者而言，这些症状并不难处理。因此，当将切除原发肿瘤作为积极联合治疗方法的一部分时，辅助性肾切除术比姑息性肾切除术是更合适的术语。接受辅助性肾切除术的患者中，仅有骨转移的患者1年生存率（36%）高于有其他部位转移的患者（18%）。接受醋酸甲羟孕酮和辅助性肾切除术治疗的患者中，12%出现转移灶完全消退。讨论了辅助性肾切除术联合栓塞性梗死、激素治疗、化疗和/或免疫治疗的作用。
